261780 — CHA Vaccine Research Institute Balance Sheet
0.000.00%
- KR₩127bn
- KR₩95bn
- KR₩294m
Annual balance sheet for CHA Vaccine Research Institute, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 8,878 | 24,827 | 61,550 | 57,763 | 38,896 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 155 | 188 | 267 | 608 | 454 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 9,038 | 25,037 | 61,847 | 58,917 | 42,486 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 355 | 587 | 1,032 | 1,543 | 1,644 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 9,556 | 25,747 | 65,313 | 61,069 | 45,119 |
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 15,259 | 4,806 | 24,706 | 26,789 | 810 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 18,382 | 24,174 | 25,698 | 27,703 | 9,702 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -8,826 | 1,573 | 39,615 | 33,366 | 35,417 |
Total Liabilities & Shareholders' Equity | 9,556 | 25,747 | 65,313 | 61,069 | 45,119 |
Total Common Shares Outstanding |